A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies

Personalized Medicine Universe Pub Date : 2015-07-01 DOI:10.1016/j.pmu.2015.03.004

Amane Sasada, Megumi Takagi, Shigeki Tabata, Minako Abe, Hiroyuki Abe

{"title":"A patient with stage IV gastric cancer who acquired complete remission after undergoing multi-peptide dendritic cell immunotherapy in combination with standard therapies","authors":"Amane Sasada, Megumi Takagi, Shigeki Tabata, Minako Abe, Hiroyuki Abe","doi":"10.1016/j.pmu.2015.03.004","DOIUrl":null,"url":null,"abstract":"<div>In this report, we describe a 62-year-old male patient with stage IV gastric cancer who was treated with chemotherapy and dendritic cell immunotherapy targeting the cancer antigens WT1, MUC1, Her-2, and survivin. He then received WT1 and MUC1 peptides in combination with adjuvants near the lymph nodes or the mucosa of the cancer lesion. Subsequently, a remarkable decrease in the size of the gastric lesion, in the swelling of metastatic lymph nodes, and the disappearance of ascites were observed. After 1 year and 2 months of the initial diagnosis, the patient underwent a robot-assisted gastrectomy and was able to return to work. In conclusion, multi-peptide dendritic cell immunotherapy in combination with conventional therapies resulted in remarkable anti-cancer effects and improved the patient's quality of life.</div>","PeriodicalId":101009,"journal":{"name":"Personalized Medicine Universe","volume":"4 ","pages":"Pages 70-72"},"PeriodicalIF":0.0000,"publicationDate":"2015-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.pmu.2015.03.004","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Personalized Medicine Universe","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2186495015000085","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 4

Abstract

In this report, we describe a 62-year-old male patient with stage IV gastric cancer who was treated with chemotherapy and dendritic cell immunotherapy targeting the cancer antigens WT1, MUC1, Her-2, and survivin. He then received WT1 and MUC1 peptides in combination with adjuvants near the lymph nodes or the mucosa of the cancer lesion. Subsequently, a remarkable decrease in the size of the gastric lesion, in the swelling of metastatic lymph nodes, and the disappearance of ascites were observed. After 1 year and 2 months of the initial diagnosis, the patient underwent a robot-assisted gastrectomy and was able to return to work. In conclusion, multi-peptide dendritic cell immunotherapy in combination with conventional therapies resulted in remarkable anti-cancer effects and improved the patient's quality of life.

查看原文本刊更多论文

IV期胃癌患者在接受多肽树突状细胞免疫治疗联合标准治疗后获得完全缓解

在这个报告中，我们描述了一个62岁的男性IV期胃癌患者，他接受了化疗和针对癌症抗原WT1、MUC1、Her-2和survivin的树突状细胞免疫治疗。然后他接受WT1和MUC1肽联合佐剂在淋巴结或癌灶粘膜附近。随后，胃病变明显缩小，转移淋巴结肿大，腹水消失。经过1年零2个月的初步诊断，患者接受了机器人辅助的胃切除术，并能够重返工作岗位。综上所述，多肽树突状细胞免疫治疗联合常规治疗具有显著的抗癌效果，提高了患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Personalized Medicine Universe

自引率

0.00%

发文量